REG-FDA — Wegovy HD (Semaglutide 7.2 mg) Approval

[DRAFT — authored 2026-04-18. Regulatory reference. Medical Director review recommended.]

Source

US Food and Drug Administration press announcement, March 19, 2026. "FDA Approves Fourth Product Under National Priority Voucher Program — Higher Dose Semaglutide." Official approval of Wegovy® (semaglutide) injection 7.2 mg for chronic weight management.

External URL: FDA.gov press announcement

Corporate announcement: Novo Nordisk A/S Wegovy HD approval release

Indication

For chronic weight management in adults with obesity who have tolerated the 2.4 mg dosage for at least 4 weeks and require additional weight reduction, as an adjunct to a reduced-calorie diet and increased physical activity.

Key Regulatory Context

First GLP-1 approved under the Commissioner's National Priority Voucher pilot program. 54-day review from filing to approval.
Trial basis: STEP UP (Wharton, Kushner et al., Lancet Diabetes Endocrinol 2025;13(11):949-963, PMID-40961952 if indexed).

Clinical Results Supporting Approval

STEP UP (obesity without T2D): 20.7% mean body weight reduction at 72 weeks; ~31.2% achieved ≥25% weight loss
STEP UP T2D: 14.1% mean body weight reduction

Label Features Distinct from 2.4 mg

Dysesthesia warning: Altered skin sensation reported more frequently at 7.2 mg than at 2.4 mg. Label includes specific language on altered sensation / neurologic symptoms. Generally resolves spontaneously or with dose reduction.
Titration requirement: Patient must tolerate 2.4 mg for ≥4 weeks before escalation to 7.2 mg.
No new boxed warnings beyond class-wide MTC/MEN2 warning.

Availability

Available in April 2026 through Wegovy® distribution channels (pharmacy network ~70,000 locations in US, NovoCare® Pharmacy, telehealth, GoodRx).

Clinical Positioning Note

Wegovy HD 7.2 mg positions semaglutide closer to (but not equal to) tirzepatide 15 mg on weight-loss efficacy via cross-trial comparison (20.7% STEP UP vs. 22.5% SURMOUNT-1, PMID-35658024). No head-to-head RCT exists between Wegovy HD 7.2 mg and tirzepatide.

Linked Peptides

Semaglutide

Related Regulatory / Trial References

PMID-40961952 if indexed — STEP UP trial publication
PMID-35658024 – SURMOUNT-1 Tirzepatide for Obesity — cross-trial comparator for tirzepatide efficacy

Orchestrator Notes

Approval via Commissioner's National Priority Voucher — a new FDA accelerated-review pathway.
The dysesthesia signal at higher dose is new and warrants surveillance post-approval.
Phase 4 commitments may include specific monitoring for dysesthesia.

REG-FDA-Wegovy-HD-2026 – Wegovy 7.2 mg National Priority Voucher Approval